Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Brenner

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Blood|May 27, 2004
Targeted delivery of adenoviral vectors by cytotoxic T cellsPatricia Yotnda, Barbara Savoldo, Nicolas Charlet-Berguerand, et al.
Pediatric Hematology and Oncology|August 23, 2011
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology"Christian M Capitini, Stephen Gottschalk, Malcolm Brenner, et al.
Cancer Research|February 26, 2017
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid TumorsKiyonori Tanoue, Amanda Rosewell Shaw, Norihiro Watanabe, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 2, 2007
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactinHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastomaHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.
Blood|November 13, 2004
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytesEttore Biagi, Gianpietro Dotti, Eric Yvon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 14, 2015
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological MalignanciesSwati Naik, Caridad Martinez, Kathryn Leung, et al.
Cytotherapy|August 26, 2010
Defining the risks of mesenchymal stromal cell therapyDarwin J Prockop, Malcolm Brenner, Willem E Fibbe, et al.
Brain : a Journal of Neurology|February 27, 2004
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosisWei Sun, Uday Popat, George Hutton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Blood|May 27, 2004
Targeted delivery of adenoviral vectors by cytotoxic T cellsPatricia Yotnda, Barbara Savoldo, Nicolas Charlet-Berguerand, et al.
Pediatric Hematology and Oncology|August 23, 2011
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology"Christian M Capitini, Stephen Gottschalk, Malcolm Brenner, et al.
Cancer Research|February 26, 2017
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid TumorsKiyonori Tanoue, Amanda Rosewell Shaw, Norihiro Watanabe, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 2, 2007
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactinHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastomaHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.
Blood|November 13, 2004
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytesEttore Biagi, Gianpietro Dotti, Eric Yvon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 14, 2015
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological MalignanciesSwati Naik, Caridad Martinez, Kathryn Leung, et al.
Cytotherapy|August 26, 2010
Defining the risks of mesenchymal stromal cell therapyDarwin J Prockop, Malcolm Brenner, Willem E Fibbe, et al.
Brain : a Journal of Neurology|February 27, 2004
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosisWei Sun, Uday Popat, George Hutton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Pageof 3